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Implementing a monitoring program for patients on direct oral 
anticoagulants
• Backus Hospital Medication Management Clinic located in Norwich, CT 
provides a newly implemented Direct Oral Anticoagulant (DOAC) 
management service. 
• Patient population: patients with non-valvular atrial fibrillation or venous 
thromboembolism
• Role of clinical pharmacist: 
• Initiation of DOAC therapy
• Monitors for the efficacy and safety of DOAC therapy
• Provides education on the benefits and risks of DOAC therapy
• Pharmacist Evaluation:
• Lifestyle (diet and exercise)
• Renal function
• Drug-drug interactions and other medications use
• Clinical pharmacist communicates to the referring physicians on any 
significant concerns or recommendations with DOAC therapy.
• The referred patients will be discharged from the clinic when they have 
been on DOAC for an extended duration (typically >6 months). 
• Prior to discharge, the patients will be assessed to ensure that they are well-
educated on signs and symptoms of adverse events to DOAC agents and 
what actions to take if these events were to arise.
Service
Justification
• Many providers choose a DOAC for anticoagulation because of the ease of 
administration and fewer drug and food interactions. 
• A number of providers, however, forego any follow-up with patients on 
DOAC agents believing it is unwarranted. 
• On the contrary, a growing body of evidence and expert opinion supports 
the importance of follow-up monitoring for these patients. 
• Pharmacist interventions:
• Patients’ adherence
• Monitoring for adverse events
• Improve health outcomes 
Adaptability
• DOAC management service can be implemented in pharmacist-driven 
anticoagulation clinics. 
• Many anticoagulation clinics are already staffed with healthcare 
professionals, who are well trained at evaluating and educating patients for 
the signs and symptoms of thrombosis and bleeding.
• The same concept along with renal function monitoring is applied in this 
DOAC management program. 
Significance
• The role of a clinical pharmacist is expanding rapidly in the healthcare world 
in which the pharmacist is gaining more responsibilities as a valuable 
member of a healthcare team. Since the use of DOACs is on the rise,  DOAC 
management program driven by pharmacist will enhance patient care and 
safety along with expanding the pharmacist’s role in anticoagulation care. 
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1.Diagnosis
a. Non-valvular atrial fibrillation (NVAF)
b. Venous thromboembolism (VTE)
2.Direct Oral Anticoagulant of Choice
3.Duration of Anticoagulation Therapy
a. Indefinite, 3 months, 6 months, or 1 year
4.Other Anticoagulation Status
a. Current use of oral anticoagulant or LMWH
5.Relevant Past Medical History
Pradaxa® (dabigatran) Xarelto® (rivaroxaban) Eliquis® (apixaban) Savaysa® (edoxaban)
Class Direct thrombin (IIa) 
inhibitor
Direct Factor Xa
inhibitor
Direct Factor Xa
inhibitor
Direct Factor Xa
inhibitor
Dosing NVAF: 150 mg BID
DVT/PE: 150 mg BID 
after 5 to 10 days of 
parenteral 
anticoagulation
NVAF: 20 mg daily
DVT/PE: 15 mg BID x 21 
days, then 20 mg daily
NVAF: 5 mg BID
DVT/PE: 10 mg BID x 7 
days, then 5 mg BID
NVAF: 60 mg daily
DVT/PE: 60 mg daily 
after 5 to 10 days of 
parenteral 
anticoagulation
DOAC Monitoring Checklists
The “ABCDEF” of direct oral anticoagulant management
